Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jul;85(2):157–165. doi: 10.1054/bjoc.2001.1902

Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies

J F Thompson 1, G A Siebert 2, Y G Anissimov 2, B M Smithers 3, A Doubrovsky 1, C D Anderson 4, M S Roberts 2
PMCID: PMC2364039  PMID: 11461070

Abstract

This study sought to use a microdialysis technique to relate clinical and biochemical responses to the time course of melphalan concentrations in the subcutaneous interstitial space and in tumour tissue (melanoma, malignant fibrous histiocytoma, Merkel cell tumour and osteosarcoma) in patients undergoing regional chemotherapy by Isolated Limb Infusion (ILI). 19 patients undergoing ILI for treatment of various limb malignancies were monitored for intra-operative melphalan concentrations in plasma and, using microdialysis, in subcutaneous and tumour tissues. Peak and mean concentrations of melphalan were significantly higher in plasma than in subcutaneous or tumour microdialysate. There was no significant difference between drug peak and mean concentrations in interstitial and tumour tissue, indicating that there was no preferential uptake of melphalan into the tumours. The time course of melphalan in the microdialysate could be described by a pharmacokinetic model which assumed melphalan distributed from the plasma into the interstitial space. The model also accounted for the vascular dispersion of melphalan in the limb. Tumour response in the whole group to treatment was partial response: 53.8% (n= 7); complete response: 33.3% (n= 5); no response: 6.7% (n= 1). There was a significant association between tumour response and melphalan concentrations measured over time in subcutaneous microdialysate (P< 0.01). No significant relationship existed between the severity of toxic reactions in the limb or peak plasma creatine phosphokinase levels and peak melphalan microdialysate or plasma concentrations. It is concluded that microdialysis is a technique well suited for measuring concentrations of cytotoxic drug during ILI. The possibility of predicting actual concentrations of cytotoxic drug in the limb during ILI using our model opens an opportunity for improved drug dose calculation. The combination of predicting tissue concentrations and monitoring in microdialysate of subcutaneous tissue could help optimise ILI with regard to post-operative limb morbidity and tumour response. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: regional chemotherapy, microdialysis, isolated limb infusion, melanoma, melphalan

Full Text

The Full Text of this article is available as a PDF (98.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blöchl-Daum B., Müller M., Meisinger V., Eichler H. G., Fassolt A., Pehamberger H. Measurement of extracellular fluid carboplatin kinetics in melanoma metastases with microdialysis. Br J Cancer. 1996 Apr;73(7):920–924. doi: 10.1038/bjc.1996.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. CREECH O., Jr, KREMENTZ E. T., RYAN R. F., WINBLAD J. N. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958 Oct;148(4):616–632. doi: 10.1097/00000658-195810000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Durán García E., Santolaya R., Requena T. Treatment of malignant melanoma. Ann Pharmacother. 1999 Jun;33(6):730–738. doi: 10.1345/aph.18190. [DOI] [PubMed] [Google Scholar]
  4. Ekstrøm P. O., Andersen A., Saeter G., Giercksky K. E., Slørdal L. Continuous intratumoral microdialysis during high-dose methotrexate therapy in a patient with malignant fibrous histiocytoma of the femur: a case report. Cancer Chemother Pharmacol. 1997;39(3):267–272. doi: 10.1007/s002800050571. [DOI] [PubMed] [Google Scholar]
  5. Klaase J. M., Kroon B. B., Beijnen J. H., van Slooten G. W., van Dongen J. A. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer. 1994 Jul;70(1):151–153. doi: 10.1038/bjc.1994.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Koops H. S., Vaglini M., Suciu S., Kroon B. B., Thompson J. F., Göhl J., Eggermont A. M., Di Filippo F., Krementz E. T., Ruiter D. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol. 1998 Sep;16(9):2906–2912. doi: 10.1200/JCO.1998.16.9.2906. [DOI] [PubMed] [Google Scholar]
  7. Landaw E. M., DiStefano J. J., 3rd Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. Am J Physiol. 1984 May;246(5 Pt 2):R665–R677. doi: 10.1152/ajpregu.1984.246.5.R665. [DOI] [PubMed] [Google Scholar]
  8. Mader R. M., Brunner M., Rizovski B., Mensik C., Steger G. G., Eichler H. G., Müller M. Analysis of microdialysates from cancer patients by capillary electrophoresis. Electrophoresis. 1998 Nov;19(16-17):2981–2985. doi: 10.1002/elps.1150191630. [DOI] [PubMed] [Google Scholar]
  9. Müller M., Brunner M., Schmid R., Mader R. M., Bockenheimer J., Steger G. G., Steiner B., Eichler H. G., Blöchl-Daum B. Interstitial methotrexate kinetics in primary breast cancer lesions. Cancer Res. 1998 Jul 15;58(14):2982–2985. [PubMed] [Google Scholar]
  10. Müller M., Mader R. M., Steiner B., Steger G. G., Jansen B., Gnant M., Helbich T., Jakesz R., Eichler H. G., Blochl-Daum B. 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. Cancer Res. 1997 Jul 1;57(13):2598–2601. [PubMed] [Google Scholar]
  11. Renard N., Nooijen P. T., Schalkwijk L., De Waal R. M., Eggermont A. M., Liénard D., Kroon B. B., Lejeune F. J., Ruiter D. J. VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol. 1995 Jul;176(3):279–287. doi: 10.1002/path.1711760310. [DOI] [PubMed] [Google Scholar]
  12. Roberts M. S., Donaldson J. D., Rowland M. Models of hepatic elimination: comparison of stochastic models to describe residence time distributions and to predict the influence of drug distribution, enzyme heterogeneity, and systemic recycling on hepatic elimination. J Pharmacokinet Biopharm. 1988 Feb;16(1):41–83. doi: 10.1007/BF01061862. [DOI] [PubMed] [Google Scholar]
  13. Scott R. N., Blackie R., Kerr D. J., Hughes J., Burnside G., MacKie R. M., Byrne D. S., McKay A. J. Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion. Eur J Cancer. 1992;28A(11):1811–1813. doi: 10.1016/0959-8049(92)90009-q. [DOI] [PubMed] [Google Scholar]
  14. Sinha T., Benedict R. Relationship between latitude and melanoma incidence: international evidence. Cancer Lett. 1996 Feb 6;99(2):225–231. doi: 10.1016/0304-3835(95)04063-3. [DOI] [PubMed] [Google Scholar]
  15. Thompson J. F., Hunt J. A., Shannon K. F., Kam P. C. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. 1997 Aug;132(8):903–907. doi: 10.1001/archsurg.1997.01430320105017. [DOI] [PubMed] [Google Scholar]
  16. Thompson J. F., Kam P. C., Waugh R. C., Harman C. R. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998 Apr-May;14(3):238–247. doi: 10.1002/(sici)1098-2388(199804/05)14:3<238::aid-ssu8>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  17. Ungerstedt U. Microdialysis--principles and applications for studies in animals and man. J Intern Med. 1991 Oct;230(4):365–373. doi: 10.1111/j.1365-2796.1991.tb00459.x. [DOI] [PubMed] [Google Scholar]
  18. Vrouenraets B. C., Hart G. A., Eggermont A. M., Klaase J. M., van Geel B. N., Nieweg O. E., Kroon B. B. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg. 1999 May;188(5):522–530. doi: 10.1016/s1072-7515(99)00018-6. [DOI] [PubMed] [Google Scholar]
  19. Vrouenraets B. C., Kroon B. B., Klaase J. M., Nieweg O. E., van Slooten G. W., van Dongen J. A. Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res. 1995 Dec;5(6):425–431. doi: 10.1097/00008390-199512000-00006. [DOI] [PubMed] [Google Scholar]
  20. Vrouenraets B. C., Nieweg O. E., Kroon B. B. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg. 1996 Oct;83(10):1319–1328. doi: 10.1002/bjs.1800831004. [DOI] [PubMed] [Google Scholar]
  21. Wieberdink J., Benckhuysen C., Braat R. P., van Slooten E. A., Olthuis G. A. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982 Oct;18(10):905–910. doi: 10.1016/0277-5379(82)90235-8. [DOI] [PubMed] [Google Scholar]
  22. Wu Z. Y., Smithers B. M., Anderson C., Roberts M. S. Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment? Melanoma Res. 2000 Feb;10(1):47–54. [PubMed] [Google Scholar]
  23. Wu Z. Y., Smithers B. M., Roberts M. S. Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb. Melanoma Res. 1997 Jun;7(3):252–264. doi: 10.1097/00008390-199706000-00010. [DOI] [PubMed] [Google Scholar]
  24. Wu Z. Y., Thompson M. J., Roberts M. S., Addison R. S., Cannell G. R., Grabs A. J., Smithers B. M. High-performance liquid chromatographic assay for the measurement of melphalan and its hydrolysis products in perfusate and plasma and melphalan in tissues from human and rat isolated limb perfusions. J Chromatogr B Biomed Appl. 1995 Nov 17;673(2):267–279. doi: 10.1016/0378-4347(95)00277-5. [DOI] [PubMed] [Google Scholar]
  25. Wu Z., Roberts M. S., Parsons P. G., Smithers B. M. Isolated limb perfusion with melphalan for human melanoma xenografts in the hindlimb of nude rats: a surviving animal model. Melanoma Res. 1997 Feb;7(1):19–26. doi: 10.1097/00008390-199702000-00004. [DOI] [PubMed] [Google Scholar]
  26. de Wilt J. H., ten Hagen T. L., de Boeck G., van Tiel S. T., de Bruijn E. A., Eggermont A. M. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer. 2000 Mar;82(5):1000–1003. doi: 10.1054/bjoc.1999.1032. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES